21.80USD+0.65%Mkt Cap: 2.48B USDP/E: —Last update: 2026-05-26
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company d…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.48B USD
Enterprise Value2.02B USD
Revenue (TTM)4.01M USD
Gross Profit-182.78M USD
Net Income (TTM)-212.39M USD
Revenue/Share0.0420 USD
Last Price21.80 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees206
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.46
PEG—
EV/EBITDA-8.93
EV/Revenue503.42
P/S647.63
P/B4.41
EPS (TTM)-2.39
EPS (Forward)-2.00
52W Range
7.96070% of range27.65
52W High27.65 USD
52W Low7.960 USD
Profitability
Gross Margin0.00%
Oper. Margin-5698.83%
EBITDA Margin0.00%
Profit Margin-3059.99%
ROE-33.48%
ROA-31.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-190.92M USD
CapEx (TTM)15.93M USD
FCF Margin-3469.81%
FCF Yield-5.62%
Net Debt-579.00M USD
Net Debt/EBITDA2.56
Balance Sheet
Debt/Equity0.01
Current Ratio21.68
Quick Ratio21.26
Book Value/Sh5.202 USD
Cash/Share5.145 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)35.23 USD
Target Range30.00 USD – 40.00 USD
# Analysts13
Ownership
Shares Out.113.25M
Float108.33M
Insiders6.30%
Institutions102.28%
Short Interest
Short Ratio16.6d
Short % Float19.27%
Short % Out.16.48%
Shares Short18.66M
Short (prev mo.)18.95M
Technical
SMA 5021.99 (-0.9%)
SMA 20018.42 (+18.4%)
Beta2.12
S&P 52W Chg28.31%
Avg Vol (30d)943.69K
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—